



Proteomics International Laboratories Ltd

Ignite Investment Summit

Disciplined Path to Commercial Success

14 October 2026

ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia



Disclaimer

This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ).

You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding whether or not to seek to purchase the shares of the Company. This is not an offer to subscribe for securities in the Company.

The Presentation may contain quantitative statements of anticipated future performance such as projections, forecasts, calculations, forward-looking statements or estimates all of which are based on certain assumptions (Forward Looking Statements). The Forward Looking Statements may involve subjective judgements and are based on a large number of assumptions and are subject to significant uncertainties and contingencies, many of which are outside the control of the Company and may not prove to be correct.

No representation or warranty is made that any Forward Looking Statements will be achieved, or occur, or that the assumptions upon which they are based are reasonable or the calculations from which they have been derived are correct. Actual future events may vary significantly from the Forward Looking Statements. Each Recipient should undertake their own independent review of the Forward Looking Statements, including the assumptions on which they are based and the financial calculations from which they are derived.



Disciplined Path to Commercial Success

Proteomics International has repositioned the business for commercial execution, advancing three lead tests through validation, market access and reimbursement pathways, while maintaining disciplined capital allocation.

Transforming from research to commercial execution

Focusing the business on clear commercial priorities, stronger accountability and disciplined capital allocation.

Expanding through distribution partners

Leveraging the Healius collection network (1,900 collection centres in Australia) and referrer relationships. Engaging a US distribution partner is the next priority.

Advancing three lead tests that address unmet needs

Advancing Promarker®D, Promarker®Eso and Promarker®Endo to address unmet needs in diabetic kidney cancer, oesophageal disease and endometriosis.

Progressing reimbursement pathways

Pursuing reimbursement in Australia and the US through evidence generation and dossier development, with private pay supporting initial market access.

Targeting significant and addressable markets

Targeting sizeable patient populations and building adoption to support potential recurring test revenue.

Executing our strategic roadmap

Focusing on commercialisation, innovation, scaling processes and infrastructure, and building capabilities to create sustainable long term value.



About Us

Proteomics International (ASX: PIQ) develops proprietary blood tests for disease prediction and diagnosis. We deliver laboratory testing and clinical reporting, while distribution partners provide market access to clinicians and patients.

Target Unmet Clinical Needs



- Identify high value diagnostic gaps
- Target diseases with delayed or inadequate diagnosis
- Focus on tests that can improve clinical decision making

Leverage our Proprietary Platform



- Discover disease-associated protein biomarkers
- Combine biomarkers into proprietary test models
- Develop and clinically validate new diagnostic tests
- Protect innovation through intellectual property

Build the Promarker® Portfolio



- Promarker®D: diabetic kidney disease
- Promarker®Eso: oesophageal cancer
- Promarker®Endo: endometriosis
- Advance new tests through the development pipeline

Operate Integrated Clinical Laboratories



- Accredited NATA laboratory operations in Australia
- CLIA/CAP laboratory capability in the US
- Deliver testing, clinical reporting and quality assurance
- Scale operations to support commercial demand

Drive Market Access



- Distributor-led commercial model
- Healius partnership provides national Australian access
- Private-pay launch while reimbursement is pursued
- Build US distribution and payer access



Board of Directors

Dr James Williams Non-Executive Chair

PhD, MBA, BSc (Hons) GAICD



Seasoned life sciences executive with experience from startup to commercialisation.

Former CEO/CTO/Chair across multiple biotech companies including Dimerix and iCeutica.

Contributed to development of five FDA-approved drugs, devices, and diagnostics.

David Morris CEO & Managing Director

BBus, BAppSc, GAICD



Global healthcare and medtech executive with 25+ years experience including at Cochlear, Nanosonics and Polynovo.

Proven track record in commercial growth, product commercialisation, and international expansion.

Deep experience in strategy, regulatory pathways, and global market development across US, Europe, and Asia.

Aaron Brinkworth Non-Executive Director

BHlthSc, GAICD



Global pharmaceutical executive with 22+ years at Gilead Sciences (Nasdaq: GILD).

Led Asia Pacific commercial, market access, and strategic licensing functions.

Deep experience in scaling sales, marketing, and distribution across complex regions.

Paul House Non-Executive Director

BEng (Hons), GAICD



Senior executive with 25+ years across multinational corporations and consulting.

CEO of Imdex (ASX: IMD); former MD of SGS India and CFO/COO in global roles.

Strong track record in operational leadership, finance, and international growth.

Vicki Robinson Non-Executive Director

LLB (Hons), BCom, MAICD



Experienced non-executive and former Wesfarmers senior executive with 20+ years in legal and commercial leadership.

Served on Wesfarmers Leadership Team and as Company Secretary across group entities.

Deep experience in strategy, M&A, governance, risk, and regulatory environments.



Science of Proteomics


Genes carry the instructions. Proteins reveal how those instructions play out in health and disease. Translating that insight into reliable diagnostic and prognostic tests requires precision, standardisation and deep technical expertise.

Genes Provide the Instructions




Genes are sections of DNA that contain instructions for making proteins. Cells use these instructions to produce the proteins the body needs.

Proteins Perform Biological Functions



Proteins build and repair tissues, regulate cell activity and drive biological reactions. Proteomics studies proteins to understand what is happening in the body.

Protein Changes Signal Disease



Disease can alter the levels of particular proteins. Measuring combinations of these changes can help identify disease or assess the risk of developing it.

Measure Proteins to Detect Disease



Proteomics International identifies protein biomarkers and develops simple blood tests that measure them, to help clinicians assess disease risk and support diagnosis.



Innovation Portfolio – Four Tests

Proteomics International provides a suite of four prognostic and diagnostic tests targeting specific clinical areas of unmet need. Our priority is to validate and commercialise these tests before developing new tests for other medical conditions.

Promarker D



Prognostic blood test to predict the risk of diabetes related chronic kidney disease up to 4 years before symptoms appear, enabling earlier clinical intervention and ongoing monitoring.

Promarker Eso



Diagnostic blood test for patients with chronic reflux that detects specific protein changes to rule out oesophageal adenocarcinoma, thus reducing the need for invasive surveillance endoscopy procedures.

Promarker Endo



Diagnostic blood test for patients with symptoms suggestive of endometriosis, that reduces the extensive delays in diagnosis and management.

OxiDx



Proprietary platform for measuring oxidative stress, focusing on diagnostic or specialised applications where there is clear clinical value and economic benefits.



Innovation Portfolio – Promarker Tests

The Promarker Portfolio tests address distinct clinical pathways, supporting earlier risk identification, more targeted referral and more efficient use of healthcare resources.

	Promarker D	Promarker Eso	Promarker Endo
Clinical Value	Identifies Type 2 Diabetes (T2D) patients at higher risk of diabetic kidney disease	Triages reflux patients for endoscopy referral	Supports assessment of women with suspected endometriosis
Clinical Performance	76% Sensitivity, 92% Specificity	91% Sensitivity, 98% Specificity	Sensitivity is 90% for stage IV, 84% for stages III–IV, 80% for stages II–IV, and 68% for stages (I–IV). Specificity is 71% across all groups.
Clinical Pathway	Diabetes management and renal-risk pathways	GI referral pathways with potential to reduce unnecessary endoscopy	Women's health pathways and earlier specialist referral
Value Proposition	<i>Value from earlier intervention and lower downstream kidney disease costs</i>	<i>Value from avoiding unnecessary invasive procedures</i>	<i>Value from faster diagnosis and more efficient referral</i>


Note 1: Sensitivity (True Positive Rate), The proportion of actual positives correctly identified. Specificity (True Negative Rate) The proportion of actual negatives correctly identified. NPV (Negative Predictive Value) The probability that someone with a negative test truly does not have the condition. AUC (Area Under the ROC Curve) A summary measure of a model's ability to distinguish between classes (disease versus no disease).




Innovation Portfolio – Market Potential

We have assessed the market opportunities for our three primary tests in both Australia and the United States. Our analysis indicates that the serviceable obtainable market opportunity is substantial, offering significant growth potential.

Market Potential Australia – Annual Test Volumes ('000)



Market Potential USA – Annual Test Volumes ('000)



Definitions: Total Addressable Market (TAM) assumes unconstrained access and reimbursement. Serviceable Available Market (SAM) considers challenges associated with pathway, workflow, and reimbursement. Serviceable Obtainable Market (SOM) reflects realistic medium-term commercial penetration opportunities.


- Promarker D assumptions:** T2D patients in active care, pre-advanced CKD. Tested once every 4 years. 65% of diagnosed T2D addressable. SAM 60% of TAM; SOM 15% of SAM.
- Promarker Eso assumptions:** Chronic reflux patients with appropriate risk factors. Tested once every 3 years. 15% of managed reflux patients. SAM 70% of TAM; SOM 25% of SAM.
- Promarker Endo assumptions:** Reproductive-age women (15–49) with suspected endometriosis. Tested once per clinical work-up. 10% prevalence; 55% undiagnosed; 35% enter active work-up annually. SAM 80% of TAM; SOM 30% of SAM.

Sources: Population data from ABS and U.S. Census Bureau 2025 estimates. Promarker D: AIHW/NDSS (AU); U.S. Census Bureau/CDC (US). Promarker Eso: AIHW/RACGP (AU); NIDDK/U.S. reflux studies (US). Promarker Endo: ABS/AIHW (AU); U.S. Census Bureau/women's health literature (US).



Patient Care Ecosystem

The patient journey involves clear roles for patients, clinicians, distributors, and labs. Proteomics International handles development and testing, while partners manage market access, ensuring accountability and quality from collection to result.





Healius Distribution Partnership

Exclusive Australian pathology distribution for the Promarker® portfolio. Healius provides national market access through its collection network and referrer relationships, while Proteomics delivers testing and clinical reporting.

Strategic Rationale

- National reach through existing pathology infrastructure.
- Access established GP and specialist referrers.
- Avoid building a proprietary collection network.
- Integrate tests into routine clinical workflows.

Proteomics



- Performs testing in accredited laboratories.
- Provides clinical reporting and scientific support.
- Maintains quality and regulatory compliance.
- Leads product development and clinical evidence.



- Exclusive Australian pathology distributor.
- Approximately 1,900 collection centres.
- Collects specimens and distributes pathology services.
- Supports referrer engagement and market access.


Commercial Rollout

- Promarker D and Promarker Eso controlled market release in WA and NT on 14 Sep 2026.
- National rollout in FY27 Q2.
- Initial private pay patient prices: Promarker D A\$495 and Promarker Eso A\$997.
- Promarker Endo commercially available during FY27 Q3, pricing to be confirmed.



Strategic Framework for Execution


Enterprise objectives create a clear framework aligning strategy with execution, focusing on areas of commercial execution, innovation, operations, and organisational capabilities to deliver lasting value for patients, partners, and investors.





Execution Plan – The Next 3 Years

The strategic roadmap outlines the 3 year plan focused on commercialisation, fostering innovation, scaling processes and infrastructure, and enhancing our capabilities to achieve sustainable long term value.





Proteomics International Laboratories Ltd

APPENDIX

14 October 2026

ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia



Promarker D – Chronic Kidney Disease

Prognostic blood test to predict the risk of diabetes related chronic kidney disease up to 4 years before symptoms appear, enabling earlier clinical intervention and ongoing monitoring.

Clinical Value

Identifies high risk patients with diabetes before irreversible kidney damage occurs.

Clinical Performance

76% Sensitivity, 92% Specificity.

Intellectual Property

Global patent portfolio covering biomarkers, and clinical applications.

Market Opportunity

SOM reflects realistic medium term annual commercial opportunities. ~20,000 patients in Australia and ~390,000 in the USA.

Clinical Pathway

Blood sample taken during regular diabetes check ups guides monitoring by GPs and nephrologists and is done every 4 years.

Reimbursement

Initial private pay in Australia and the USA, with plans for insurance and public funding; obtained the CMS PLA code in USA.

Key Actions

- **Execute the Australian rollout** with Healius to drive test adoption.
- Appoint a **US distribution partner** to establish market access.
- Engage the clinical advisory board in **clinical development and education**.
- Pursue **reimbursement in Australia and US** to enable funded access.
- Expand **lab capacity** with demand to reduce turnaround times.


Note 1: Sensitivity (True Positive Rate), The proportion of actual positives correctly identified. Specificity (True Negative Rate) The proportion of actual negatives correctly identified. NPV (Negative Predictive Value) The probability that someone with a negative test truly does not have the condition. AUC (Area Under the ROC Curve) A summary measure of a model's ability to distinguish between classes (disease versus no disease).

Note 2: CMS (Centers for Medicare & Medicaid Services). PLA (Proprietary Laboratory Analysis) A code recognised by CMS that uniquely identifies a specific proprietary clinical laboratory test for Medicare pricing and billing purposes.



Promarker D – Chronic Kidney Disease

Promarker D enables a shift from reactive CKD treatment to proactive risk-based care, identifying risk earlier, guiding targeted intervention, and helping reduce late-stage cost burden.





Promarker Eso – Oesophageal Cancer

Minimally invasive diagnostic blood test for patients with chronic reflux that detects specific protein changes to rule out oesophageal adenocarcinoma, reducing the need for invasive surveillance endoscopy procedures.

Clinical Value

Identifies patients with chronic reflux at risk of oesophageal cancer, reducing the need for invasive surveillance endoscopic procedures.

Clinical Performance

91% Sensitivity, 98% Specificity.

Intellectual Property

Globally granted patent family protecting key biomarkers and clinical applications.

Market Opportunity

SOM reflects realistic medium term annual commercial opportunities. ~15,000 patients in Australia and ~240,000 in the USA.

Clinical Pathway

Blood sample taken during regular check ups guides monitoring by GPs and gastroenterologists and is done every 3 years.

Reimbursement

Initial private pay in Australia and the USA, with plans for insurance and public funding.


Key Actions

- **Execute the Australian rollout** with Healius to drive test adoption.
- Appoint a **US distribution partner** to establish market access.
- Engage the clinical advisory board in **clinical development and education**.
- Pursue **reimbursement in Australia and US** to enable funded access.
- Expand **lab capacity** with demand to reduce turnaround times.



Promarker Eso – Oesophageal Cancer

Promarker Eso could shift oesophageal cancer risk assessment from procedure-led surveillance to a faster, lower-burden blood-test triage pathway.





Promarker Endo – Endometriosis

Diagnostic blood test for patients with symptoms suggestive of endometriosis, thus reducing the extensive delays in diagnosis and management.

Clinical Value

Identifies patients with a high risk of endometriosis, shortening the typical 7-10 year delay in diagnosis.

Clinical Performance

Sensitivity is 90% for stage IV, 84% for stages III–IV, 80% for stages II–IV, and 68% for stages (I–IV). Specificity is 71% across all groups.

Intellectual Property

Broad international patent portfolio with initial patents secured.

Market Opportunity

SOM reflects realistic medium term annual commercial opportunities. ~50,000 patients in Australia and ~360,000 in the USA.

Clinical Pathway

Blood sample is taken to help GPs and gynaecologists evaluate patients who may have endometriosis.

Reimbursement

Initial private pay in Australia and the USA, with plans for insurance and public funding.


Key Actions

- Complete applicable quality, accreditation and regulatory requirements and **prepare for clinical deployment.**
- **Execute the Australian rollout** with Healius to drive test adoption.
- Appoint a **US distribution partner** to **establish market access.**
- Engage the clinical advisory board in **clinical development and education.**
- Pursue **reimbursement in Australia and US** to enable funded access.



Promarker **Endo** – Endometriosis

Promarker Endo could shorten the path from symptoms to clarity, using a blood-test risk triage to support earlier referral and more targeted care.





OxiDx – Oxidative Stress Platform

Proprietary platform for measuring oxidative stress, focusing on diagnostic or specialised applications where there is clear clinical value and economic benefits.

Clinical Value

Provides an objective measurement of oxidative stress in specialised environments where standardised tests are unavailable.

Clinical Performance

Established platform technology with performance assessed on a per indication basis.

Intellectual Property

Patents granted across key markets.

Market Opportunity

SOM reflects realistic medium term annual commercial opportunities. ~60,000 tests in Australia and ~1,200,000 test in the USA.

Clinical Pathway

Blood sample is taken to help doctors or specialists evaluate patient's oxidative stress levels and manage changes over time.

Reimbursement

Initial private pay in Australia and the USA.

Key Actions

- Continue to collect **clinical and real world evidence**
- Develop elite athlete and equine **business models** and confirm priority segments
- **Confirm capital investment** required to progress from research stage to a commercial business
- **Determine strategic options** and best approach to commercialisation and technology development


1. **OxiDx assumptions:** 25,000 elite athletes in Australia. 500,000 elite athletes in the USA. Assume 12 tests per year. SAM 65% of TAM; SOM 30% of SAM. Does not include Equine market potential.



Distribution Partnerships to Accelerate Adoption

The distributor model delivers faster adoption, lower execution risk, and superior capital efficiency compared to any direct or hybrid alternative.

Characteristics of the Distribution Model



Key Success Factors


- **Builds upon experiences** from earlier direct and hybrid models
- Leverages trusted **diagnostic and provider networks**
- **Avoids costs, complications, and risks** associated with proprietary infrastructure
- **Integrates seamlessly** into current clinical workflows
- Reduces **operational and compliance risks** through proven and validated platforms
- Establishes a **scalable and repeatable commercial model** to support long term growth



Reimbursement Pathways – Australia

Australia provides a national reimbursement framework for prognostic and diagnostic tests. Achieving Medicare Benefits Schedule (MBS) listing is a medium term objective that will serve as a significant driver of growth.

Reimbursement Process



Key Considerations


- A national reimbursement framework for tests is established
- Company tests are gathering clinical and health economic evidence
- MBS listing is a key medium term growth objective
- MSAC may approve, delay, or reject pending more evidence
- Timelines are long, but understood
- MBS listing secures long term patient access



Reimbursement Pathways – USA

In the United States, reimbursement for prognostic and diagnostic tests are decentralised and based on evidence, growing incrementally through private and public funding.

Reimbursement Process



Key Considerations

- The USA has no unified reimbursement system; coverage is split between Medicare, Medicaid and various private payers
- Ongoing engagement with multiple payers is essential
- Early progress often comes from private payers and hospital networks
- Reimbursement and coverage timelines differ and expand over time
- Unlike Australia's MBS, the USA requires multiple negotiations with many payers

Note 1: MoIDX (Molecular Diagnostic Services Program) A CMS program that evaluates molecular tests to determine if they are reliable, clinically useful, and medically necessary for Medicare coverage. CMS (Centers for Medicare & Medicaid Services) The U.S. federal agency that oversees Medicare and sets national coverage policies. MAC (Medicare Administrative Contractor) Regional contractors that process claims and make local coverage decisions for Medicare. LCD (Local Coverage Determination) A region-specific policy that defines when a service or test is covered by Medicare.

Proteomics International Laboratories Ltd



ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia